Atavistik Bio
Drug Discovery · Prescription Drugs
$220Mtotal raised · 3 rounds on record
$120Mlatest round · Series B · Dec 2025 · 10 mo ago
2backers · RA Capital Management, Nextech Invest
35team · US Form 5500 (plan participants) · Dec 2025 · 0% in a year
Overview
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation of disease-causing proteins, with the potential to offer transformative treatment for patients with serious diseases.
Funding and backers
Total raised
$220M
3 rounds on record
Latest round
$120M
Series B · Dec 2025 · 10 mo ago
Team
35
US Form 5500 (plan participants) · Dec 2025 · 0% in a year
Backers
2
RA Capital Management, Nextech Invest
The money's age
Fresh money
10 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 30
Partnership Atavistik Bio Partners With Cure HHT Clinical Trial Network To Advance Development Of ATV-1601 For Hereditary Hemorrhagic Telangiectasia · menafn
Dec 17, 2025
Raised a round Series B $120M
Sep 15, 2025
New executive Atavistik Bio Expands Leadership Team with Appointment ofSusan Pandya, M.D., as Chief Medical Officer · YahooFinance
Dec 25, 2023
Raised a round Venture round $40M · Pulse 2.0
Aug 24, 2021
Raised a round Series A $60M
2021
Founded
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Dec 2025 | $120M | — | manilatimes.net |
| Venture round | Dec 2023 | $40M | — | Pulse 2.0 |
| Series A | Aug 2021 | $60M | — | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
LifeMine is a clinical-stage biopharmaceutical company pioneering a bold new approach, Top-Down Drug DiscoveryTM, which leverages…
We are bringing more disease-causing targets within the reach of small molecule therapeutics to transform care for patients with…
Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of…
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key…
Advancing medicines to restore homeostasis. Cajal Therapeutics is developing novel medicines for serious diseases, including anemias of…
GH Research is a clinical-stage pharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Salary insights
Compensation ranges based on this company's open jobs
Median
$290k
Typical range
$290k
Open positions
1
1
Jobs
Senior
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 1 | $290k | $290k |
Highest paying role
Sr. Director, Biostatistics
$290k
Normalized to USD per year
Visa sponsorship
0
H-1B filings in 12 months
1
Open roles in United States
In the register as Atavistik Bio, Inc., Cambridge, MA (+1 more)
Other sponsors in the same field
Exelixis 33 filings
Recursion Pharmaceuticals 3 filings
Arrowhead Pharmaceuticals 2 filings
Iambic Therapeutics 1 filings
See 1 open role Alert me
US Department of Labor · latest filing Mar 14, 2025 · Visa details by country
Growth
Hiring Momentum
25/100
Slowing
Open positions
1
0 opened / 1 closed in 30 days
Median time-to-fill
37 days
faster than 36% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
100% ▲
Tech stack
Technologies named in job postings at Atavistik Bio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
1
Stack modernity
53/100
Practices & domains
CRISPR
Western Blot
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Nextech InvestVia a fund
63 portfolio companies: Zymeworks, Vividion Therapeutics (Acquired), Zenith Therapeutics and 60 more
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference
Updated preclinical data and clinical trial-in-progress poster from the Harmony-HHT Phase 1/2 trial support the ongoing development of ATV-1601, an investigational oral allosteric inhibitor that selectively targets AKT1 to address the underlying disease b
Read more
Report
Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roche PharmExec
Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.
Read more
Report
Atavistik Bio, Roche Partner To Develop Novel Therapies For Cardiometabolic Diseases
Atavistik Bio, a clinical-stage biotechnology company focused on discovering new medicines through its proprietary allosteric drug discovery platform has entered into a strategic research collaboration with Roche (RHHBY) to identify and develop novel smal
Read more
Report
Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics
Collaboration leverages Atavistik Bio's proprietary AMPSTM platform to identify and advance novel allosteric small molecules against multiple targ...
Read more
Report
Atavistik Bio, Inc. and Roche Announce Strategic Research Collaboration to Discover and Develop Novel Allosteric Therapeutics
Read more
Report
Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop ...
Read more
Report
Atavistik Bio partners with Cure HHT Clinical Trial Network to advance development of ATV-1601 for hereditary haemorrhagic telangiectasia
Atavistik Bio partners with Cure HHT Clinical Trial Network to advance development of ATV-1601 for hereditary haemorrhagic telangiectasia
Read more
Report
Atavistik Bio Partners With Cure HHT Clinical Trial Network To Advance Development Of ATV-1601 For Hereditary Hemorrhagic Telangiectasia
Read more
Report
Atavistik Bio Announces U.S. FDA Clearance Of Investigational New Drug Application And Fast Track Designation For ATV-1601 For The Treatment Of Hereditary Hemorrhagic Telangiectasia (HHT)
Read more
Report
Atavistik Bio: $120 Million Series B Raised To Advance Selective Allosteric Small-Molecule Programs In HHT And MPNs
Atavistik Bio said it raised a $120 million Series B financing to push two selective allosteric small-molecule programs into clinical proof-of-concept studies: an oral, AKT1-selective allosteric inhibitor for hereditary hemorrhagic telangiectasia (HHT) an
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Cambridge
Cambridge
United States
HQ
1 open roles 1 posted in 90 days 50-200 est. staff $290k Avg Salary
hires for Healthcare